Lung cancer is the third most common cancer in the UK, with around 47,200 people diagnosed each year. There are two main types of lung cancer – small-cell lung cancer and non-small-cell lung cancer – depending on how the cells look under the microscope.
The main symptoms are a cough, shortness of breath and weight loss.
One of the biggest meetings of the world’s cancer specialists took place this weekend. Usually located in Chicago, researchers and clinicians around the world met virtually this year to present the latest in cancer research at the American Society of Clinical Oncology (ASCO) annual meeting. Here’s a flavour of the some of the top research presented.
Reluctance to attend hospital tests and come forward about symptoms could be contributing to delays in lung cancer diagnosis.
Health officials are urging people to get symptoms checked, after figures suggest that thousands of people in England could have undiagnosed lung cancer.
A potentially life-extending treatment for some people with non small cell lung cancer (NSCLC) will now be available on the NHS in England.
The three latest SMC decisions will provide new treatment options for some adults with non small cell lung cancer, multiple myeloma and a rare type of lymphoma.
Confusion over the symptoms of lung cancer and COVID-19 may be responsible for a drop in the number of people being referred for lung cancer tests in Wales.
At least 14,000 fewer people have been urgently referred for lung cancer tests since March.
The National Institute for Health and Care Excellence has approved the drug osimertinib to treat some adults in England with untreated, advanced lung cancer.
New data suggest that targeted therapy seems to be having an impact on the treatment of lung cancer.